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proliferated beyond 5th and 6th cell-divisions respectively, whereas
the lovastatin treatment reduced the number to 31% and 48%
respectively. In summary, we demonstrated here that lovastatin
prevents both homing and proliferating of donor-derived T cells in
the secondary lymphoid organs, which are crucial sites for allo-
reactive expansion. While most of the control mice died of acute
GVHD within the ﬁrst week of post-transplant when alloreactive
T cells inﬁltrated the targeted organs, lovastatin treatment pre-
vented the activation and expansion of donor-derived T cells, and
thus reduced the GVHD mortality and morbidity. Our study
provides rationale for a potential novel treatment for GVHD.
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EXPRESSION OF STAT1 DURING GRAFT-VERSUS-HOST DISEASE
(GVHD)
Ziegler, J.A.1, Lokshin, A.2, Bedeir, A.3, Sepulveda, A.3, Lentzsch, S.1,
Mapara, M.Y.1 1University of Pittsburgh Cancer Institute, Pittsburgh,
PA; 2University of Pittsburgh,Luminex Facility, Pittsburgh, PA; 3Uni-
versity of Pittsburgh, Department of Pathology, Pittsburgh, PA.
The role of the IFN-g in the development of GVHD is enig-
matic due to an abundance of partially contradicting results.
Whereas there is evidence that GVHD can occur in the absence of
IFN-g, it has been demonstrated in preclinical BMT models that
IFN-g may accelerate or mitigate GVHD depending on the ex-
perimental setting. We have focused on the role of STAT1 in the
development of GVHD, the major signaling pathway of IFN-g.
We studied STAT1 and p-STAT1 (Tyr701) expression by immu-
nohistochemistry in the GVHD target organs liver, small bowel
and colon following induction of GVHD and correlated these
ﬁndings with the presence of lamina propria (LP) lymphocytes,
typical features of GVHD-induced tissue damage and expression of
tissue cytokines/chemokines. GVHD was induced in the fully
MHC mismatched BALB/c to B6 strain combination following
lethal irradiation with 975 rad. As detected by western blots p-
STAT1 expression became detectable on day 1 in the spleen and
on days 3 in the liver, small bowel and colon. Compared to
untreated controls immunohistochemical p-STAT1 staining be-
came apparent on day 3 post-BMT in the small bowel and colon
of syngeneic controls and GVHD animals. Whereas p-STAT1
expression was only transient in syngeneic controls, a further in-
crease in p-STAT1 staining was observed in GVHD animals in the
colon and small bowel on day 6. In the colon this signiﬁcant
increase in crypt cell p-STAT1 staining was associated with the
presence of LP inﬁltrating lymphocytes and coincided with the
maximal features of tissue damage (luminal sloughing, crypt de-
struction and crypt apoptosis). In line with these results IFN-g
protein expression became detectable in colon tissue lysates on day
6 supporting the role of IFN-g producing inﬁltrating donor T
cells in causing STAT1 activation and tissue damage. We conclude
that in comparison to untreated controls STAT1 activation can be
observed in the colon and small bowel starting on day 3 in
animals with GVHD and syngeneic controls. Whereas pSTAT1
staining peaks at day 3 in syngeneic controls and declines there-
after, maximal STAT1 activation occurs in GVHD animals on day
6 , coincides with detectable IFN-g expression and is accompa-
nied by LP inﬁltration and features of severe GVHD-related tissue
damage. To fully understand the role of IFN-g in the development
of gut GVHD further studies are warranted to delineate the role of
STAT1 dependent and independent signaling pathways in the
development of GVHD.
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THE PREDICTIVE VALUE OF GENE EXPRESSION PROFILES FOR ACUTE
GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANS-
PLANTATION WITH NONMYELOABLATIVE CONDITIONING FOR HEMA-
TOLOGICAL MALIGNANCY
Masmas, T.N.1, Friis-Hansen, L.2, Petersen, S.L.1, Schjerling, C.K.2,
Hansen, F.C.2, Vindelov, L.L.1 1Allogeneic Hematopoietic Cell Trans-
plantation Laboratory, Department of Hematology, Rigshospitalet,
Copenhagen, Denmark; 2Department of Clinical Biochemistry, Rigshos-
pitalet, Copenhagen, Denmark.
Purpose: To test the hypothesis that global gene expression
proﬁles of peripheral blood mononuclear cells (PBMNC) day 14
after hematopoietic cell transplantation (HCT) with nonmyeloab-
lative conditioning could predict the later occurrence of acute
graft-versus-host disease (aGVHD) grade II-IV.Material:Ninety-
eight patients with hematological malignancies received HCT with
peripheral blood stem cells from an HLA-identical sibling/mother
donor (N64/1) or from a matched unrelated donor (N33)
following nonmyeloablative conditioning with low dose ﬂudara-
bine and 2 Gy of total body irradiation. Post-transplant immuno-
suppression consisted of cyclosporine and mycophenolate mofetil.
Among these patients, 16 patients never experiencing aGVHD and
16 patients experiencing aGVHD grade II-IV before day 70
(range 21-70) were selected.Methods: RNA was precipitated from
frozen PBMNC from day 14 post-transplant and gene proﬁling
analyses were performed using Human Genome U133 Plus 2.0
GeneChip Array. The array data were normalized and GCMA
modelled in R, log2 transformed, corrected for batch variation, and
subsequently imported into dChip for further analysis. Results:
The diffentially regulated gene expression between the two groups
was identiﬁed and formed the basis for the subsequent principal
component analysis. This separated more than 85% of patients
who experienced aGvHD from those who did not. Conclusion:
Albeit preliminary, these data suggest that pattern of gene expres-
sion proﬁles early post-transplant seems to be able to predict
patients with high risk of later occurrence of aGVHD from those
never experiencing aGVHD in this retrospective study. This
knowledge could be exploited to increase the immunosupression
and thus prevent aGVHD in patients at risk. Furthermore, this
method could help identify candidate genes of interest for the
pathogenesis of aGVHD.
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DENDRITIC CELL TYPE 2 COUNTS ON DAY 28 IN HLA-MATCHED
RELATED ALLOGENEIC PBSCT PREDICTS THE INCIDENCE OF ACUTE
AND CHRONIC GVHD
Rajasekar, R.1, Mathews, V.1, Lakshmi, K.M.1, Viswabandya, A.1,
George, B.1, Chandy, M.1, Srivastava, A.1 1Christian Medical College,
Vellore, Tamil Nadu, India.
Dendritic cells (DC) are antigen-presenting cells involved in
induction and regulation of immune responses. We investigated
the impact of the number of infused and engrafted (day 28) den-
dritic cells, DC1 (lin-HLA-DRCD11c) and DC2 (lin-HLA-
DRCD123), on the development of acute and chronic GVHD.
68 patients who underwent HLA matched related G-CSF mobi-
lized allogeneic PBSCT were included in the analysis. The median
age was 28 years (range: 3-55) and there were 43 (63%) males.
Conditioning regimen was myeloablative in 34 (Bu/Cy20; Cy/
TBI  14) and reduced intensity in the rest (Flu/Mel 12; Flu/Cy
15; Flu/Cy/ATG 3; Flu/Bu/Cy1; Flu1; Ida/Flu/Cyto-
sine2). All patients received cyclosporine and short course meth-
otrexate as GVHD prophylaxis. 23 patients developed acute
GVHD (grade II-IV) and 21 patients had chronic GVHD. Twelve
patients received steroids before day 28 for treatment of GVHD.
Seven patients died before day 28 and were excluded from the
analysis; 2 of these patients had acute GVHD. On a univariate
analysis day-28 total DC, DC1 and DC2 were signiﬁcantly asso-
ciated with development of acute and chronic GVHD while graft
total DC, DC1 and DC2 did not show a similar association. Using
a ROC curve plot analysis, cutoff values for day-28 DC (Total
DC10.7/ul, DC19.7/ul and DC2  4.5/ul) gave the highest
likelihood ratios for acute GVHD (2.77, 2.14and 3.29 respec-
tively). These cut off values signiﬁcantly discriminated patients
probability of developing acute and chronic GVHD on a univariate
analysis. On a multivariate analysis, a low day-28 DC2 (4.5/ul)
together with patient age retained their risk for acute GVHD
(HR67.74 and 1.05, P-values 0.000 and 0.042 respectively), while
for chronic GVHD only a low day-28 DC2 remained signiﬁcant
(HR12.8, P0.005). Using the DC2 cutoff value of 4.5/ul, pa-
tients were categorized into a high ( 4.5/ul) (n31) and a low
DC2 (4.5/ul) (n30) group. These two groups were comparable
with regard to age, sex, FM, conditioning regimen and graft
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characteristics (CD34, CD3, CD19, NK, DC1and DC2 cell dose).
Survival curve analysis by a log rank test revealed that the low DC2
group had a signiﬁcant risk of developing acute and chronic
GVHD (P0.000 for both). These results suggest that the DC2
count in the peripheral blood on day-28 is a strong predictor for
development of GVHD in recipients of PBSC in a matched related
allogeneic SCT.
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A CDNA-BASED ASSAY FOR DONOR-CHIMERISM ANALYSIS OF EPIDER-
MAL LANGERHANS CELLS
Bakhtiar, S.1, Bender, K.2, Schmitt, T.1, Moench, C.3, Konur, A.1,
Huber, C.1, Herr, W.1, Meyer, R.G.1 1Johannes Gutenberg University,
Mainz, Germany; 2Johannes Gutenberg University, Department of
Legal Medicine, Mainz, Germany; 3Johannes Gutenberg University,
Department of Transplantation Surgery, Mainz, Germany.
Early acute GVHD of the skin frequently occurs in patients after
allogeneic hematopoietic stem cell transplantation. T cell depletion
sufﬁciently reduces incidence and severity, but does not completely
prevent skin GVHD which then leads to a prolonged need for im-
munosuppressive medication. The activation of donor T cells by
residing host antigen presenting cells such as epidermal Langerhans
cells (LCs) plays a central role in the initiation of acute GVHD. The
absence of donor T cells after depletion delays the switch of LCs from
host to donor origin in mice. We and others have provided evidence
for a delayed switch in LC chimerism after T cell depleted reduced
intensity stem cell transplantation in humans. However, most assays
used so far either depend on the detection of the Y-chromosome in
skin sections of sex-mismatched transplants. In an attempt to set up a
sensitive assay of general applicability, we combined the detection of
donor chimerism and tissue speciﬁc markers in a single multiplex
PCR. We established RT-PCRs for 10 different constitutively ex-
pressed genes containing single nucleotide polymorphisms (SNPs)
inside their coding regions. These PCRs were combined in a single
multiplex PCR and the SNPs were analyzed by the primer extension
method (minisequencing) and separated by capillary electrophoresis.
We tested this approach on PBMCs of 10 patients and their HLA-
matched sibling donors. The assay distinguished all pairs in 1 to 6 out
of 10 systems. In a subsequent step, the 10plex PCR was combined
with the tissue speciﬁc markers langerin for LCs and cytokeratin 10 to
distinguish LCs from keratinocytes. The expression of langerin and
cytokeratin 10 was detected using gene-speciﬁc probes in the same
minisequencing reaction used for the detection of SNPs. The result-
ing 12plex assay distinguished sibling donors from the patients with
the same speciﬁcity and, in the same reaction, detected Langerin as
well as cytokeratin 10 in puriﬁed LCs and keratinocytes, respectively.
In summary, we established a sensitive assay allowing simultaneous
detection of donor chimerism together with the tissue speciﬁcity of
isolated LCs that is independent of sex-mismatched donors. The
addition of further tissue speciﬁc markers might allow performing
chimerism studies on other tissue resident antigen presenting cells.
The use of a cDNA-based assay might also allow combining chimer-
ism analysis with activation- and maturation speciﬁc markers in a
single assay.
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SELECTIVE DEPLETION OF ALLOREACTING T CELLS BY TH9402-BASED
PHOTODEPLETION AS A TRANSLATIONAL STRATEGY FOR GVHD CON-
TROL IN HLA-MISMATCHED AND MATCHED DONOR-RECIPIENT PAIRS
Mielke, S.1, Nunes, R.1, Rezvani, K.1, Fellowes, V.S.2, Fan, Y.2,
Scotto, C.3, Solomon, S.P.1, Read, E.J.2, Barrett, A.J.1 1Stem Cell
Allotransplantation Section, Hematology Branch, NHLBI, NIH, Be-
thesda, MD; 2Cell Processing Section, Department of Transfusion Med-
icine, NIH, Bethesda, MD; 3Celmed Biosciences Inc., Saint-Laurent,
QC, Canada.
Selective depletion (SD) is a strategy to eliminate host-reactive
donor lymphocytes from blood stem cell allografts to prevent GVHD
and maintain GVL-effects. We investigated a photodepletion (PD)
process, whereby allo-activated donor cells are labeled with a photo-
sensitizing rhodamine-based dye, 4,5-dibromorhodamide 123
(TH9402), and exposed to visible light, which preferentially elimi-
nates allo-activated dye-retaining cells. Stimulator cells were prepared
from recipient-derived leukapheresis mononuclear cells (MNCs) and
cultured using anti-CD3 and 100 IU IL-2/ml. Responder cells (leu-
kapheresis MNCs) from 3 random HLA-mismatched volunteers and
3 HLA-matched sibling donors were cocultured 1:1 with irradiated
stimulators for 3 days. Cultured cells were incubated with 7.5 	M
TH9402, followed by dye-extrusion and exposure to 5 Joule light
energy in the PD light source (Celmed Bioscience Inc., Canada) at
510
6
cells/ml in FEP plastic bags. Depletion efﬁcacy was studied by
mixed lymphocyte reactions (MLR) in mismatched pairs and by help-
er-T-lymphocyte precursor (HTLp) frequency assay in matched
pairs. All six clinical-scale experiments provided sufﬁcient reduction of
allo-reactivity and retention of third party responses as measured
against a pool of 5 donors. In mismatched pairs mean reduction of
allo-reactivity was 703-fold ( 141) when compared to unmanipu-
lated donors. Third-party responses were maintained, with a mean
reduction of only 1.3  0.15-fold. In matched pairs alloreactivity was
reduced below the “GVHD-threshold” of 1/100.000 whilst third
party responses remained above 1/10.000 precursors. This establishes
a clinical scale PD process capable of highly efﬁcient removal of
alloreactive lymphocytes from mismatched and matched MLRs while
maintaining desirable third party responses. As PD targets activation-
based changes in MDR-1 that result in an altered dye efﬂux, the
mechanism of action is distinct from surface-marker-based allodeple-
tion (e.g. CD69, CD25). Thus, PD may overcome instability of
activation-based surface marker expression resulting in more consis-
tent and effective depletion. This approach will now be tested in a
clinical SD trial.
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PHARMACOKINETICS (PK) OF MYCOPHENOLATE MOFETIL (MMF) IN
PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (ALLOSCT) RECIP-
IENTS
Militano, O.1, Hedgpeth, D.2, Shaw, L.M.5, Figurski, M.5,
Satwani, P.2, Ayello, J.2, Roman, E.2, Bradley, B.2, George, D.2,
Garvn, J.2, Bhatia, M.2, Wolownick, K.2, Foley, S.2, Hawkes, R.2,
Cairo, M.S.2,3,4 1Department of Pathology, NewYork-Presbyterian, Co-
lumbia University; 2Pediatrics; 3Medicine; 4and Pathology; 5Pathology
and Laboratory Medicine, University of Pennsylvania.
MMF PK in children may impact on the incidence of moderate/
severe acute GVHD following AlloSCT (Osunkwo/Cairo et al,
BBMT 2004). The objective of this study is to evaluate effects of age
on the PK of MMF in pediatric AlloSCT recipients. From 1/04 –
8/06 we enrolled 31 pediatric AlloSCT with 27 being evaluable: mean
age 8.5 yrs; wt 34.3 kg; M:F12:15; NBL PR (n3), SCD (n3),
AML (CR1 [n4], CR2 [n1], CR3 [n1], relapsed/induction fail-
ure [n3]), SAA (n5), CML CP (n1), ALL (CR1 [n1], CR2
[n2], CR3 [n1]), HD CR2 (n1), ALCL refractory (n1); donor
sources: MFD (6/6 PBSC [n7], 6/6 BM [n3], 5/6 PBSC [n3]),
6/6 related CB (n1), UCB (6/6 [n2], 5/6 [n3], 4/6 [n7]), and
8/10MUDPBSC (n1). Cohort 1 [ 6 yrs] (n8); 2 [6-12 yrs of age]
(n9); 3 [12–16 yrs] (n10). GVHD prophylaxis included tacrolimus
(onDay –1 or 1st day of conditioning to maintain concentrations 5-20
ng/mL) and MMF (900 mg/m2 IV Q6H starting on Day 1, then
converted to PO [same dose] after Day14). Serum samples forMPA
were drawn on Day 1, 7, and 14 at hour 0, 0.5, 1, 2, 3, 4, and 6
post-dose. MPA plasma concentrations were determined by reverse-
phase HPLC.MMF dose was adjusted to maintainMPA trough 1-3.5
mg/L. The mean CD34 cell dose/kg 27.5105, TNC dose/kg
50.3107. Time to neutrophil (ANC  500/mm3 x 2 d) and platelet
engraftment (untransfused count  20K x 7 d) was 22 d and 36 d,
respectively. Mean f/u was 448 d. Mean MPA PK on Day 14:
Cmax17.6 mg/L, Tmax1.82 h, total MPA trough0.85 mg/L,
AUC0-639.4 mg  hr/L, T1/21.3 h, Vd1.5 L/kg, and CL1.2
L/kg/h at a mean MMF dose of 1056 mg/m2 IV Q6H. Age cohorts
are shown in Table 1. Incidence of GI adverse events attributable to
MMF was 59% (nausea/vomiting [n13], diarrhea [n8], abdominal
pain [n3], pneumatosis intestinalis [n1], gastritis/colitis [n2]).
Kaplan-Meier probability of grade II-IV aGVHD following related
[n14] and unrelated [n13] donors was 60.8% (15/27 evaluable pts),
cGVHD was 25.2% (5/22 evaluable pts) and 1 year OS was 64.4%
(CI: 45.6-83.1%). In comparison to MMF PK in adult AlloSCT pts
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